STAT3 and ovarian carcinoma: Inhibition of STAT3 signaling reduces IL-4, IL-6, and TNF-α production with a significant increase in anti-inflammatory IL-10 levels, creating an imbalance between Treg/Th17 cells, thus establishing the immunosuppressive microenvironment which promotes ovarian cancer progression [104].